Looking Back And Moving Forward In The Fight Against SARS-CoV-2
By Eric S. Langer, Managing Partner, BioPlan Associates, Inc., Christopher Murphy, Vice President/General Manager, Viral Vector/Pharma Services, Thermo Fisher Scientific, Brandon Pence, Vice President/General Manager, Purification and Pharma Analytics, Thermo Fisher Scientific, Chris Williams, Vice President/General Manager, Single-Use Technologies, Thermo Fisher Scientific, Kate Torchilin, Vice President/General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific
The unprecedented global crisis brought on by SARS-CoV-2 has affected all aspects of life and business. This includes the pharmaceutical industry, where existing trends that were driving incremental changes prior to the pandemic have been accelerated to meet the demand for SARS-CoV-2 vaccine production and delivery. A recent study by BioPlan Associates takes a closer look at the impact of SARS-CoV-2 on bioprocessing, specifically the near- and lo